×
Telesis Bio Total Liabilities 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Telesis Bio total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Telesis Bio Total Liabilities 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Telesis Bio total liabilities from 2021 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$153.4B
Gilead Sciences (GILD)
$121.1B
Bristol Myers Squibb (BMY)
$119.6B
Vertex Pharmaceuticals (VRTX)
$118.9B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$74B
GSK (GSK)
$73.1B
Argenex SE (ARGX)
$39.8B
Alnylam Pharmaceuticals (ALNY)
$35B
BioNTech SE (BNTX)
$29.7B
BeiGene (ONC)
$22B
Illumina (ILMN)
$21.1B
Biogen (BIIB)
$21B
Moderna (MRNA)
$15.2B
Incyte (INCY)
$14.3B
Insmed (INSM)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GNMSF)
$13B
Genmab (GMAB)
$13B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.7B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Exact Sciences (EXAS)
$10.4B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.9B
Exelixis (EXEL)
$9.5B
Repligen (RGEN)
$9.3B
Roivant Sciences (ROIV)
$8.1B